Ivo Timmermans

Ivo Timmermans has a comprehensive and diverse work experience spanning over several decades. Their most recent position is as the Chief Executive Officer at Pleco Therapeutics BV, where they have been since July 2018. Prior to this, they served as the Interim Head of Clinical Development - pain at Mundipharma Research Limited from December 2017 to June 2018. From February 2016 to November 2017, they held the role of Chief Medical Officer at Clinigen Group. Before that, Ivo Timmermans worked as the Medical Director for Germany, Austria, Switzerland, and the Netherlands at The Medicines Company from September 2015 to February 2016.

Before their tenure at the Medicines Company, Ivo Timmermans founded and managed their own company, Ivo Timmermans BV, where they held the position of Medical Marketing Advisor and Business Developer for 12 years, from 2003 to 2015.

Furthermore, Ivo Timmermans has experience as the Global Medical Director at Rhein Biotech NV from January 2001 to October 2002, and as the Clinical Research Manager at BASF Pharma from September 1999 to December 2000. Ivo also held various positions at GlaxoWellcome, including Senior Medical Strategy Head from September 1995 to October 1997, Medical Director Scandinavia at Wellcome Pharmaceuticals from January 1994 to September 1995, and Clinical Research Physician at Wellcome Pharmaceuticals from April 1991 to December 1993.

Earlier in their career, Ivo Timmermans worked as a Medical Adviser at the Dutch Centre for Drugs and Sports (NeCeDo) from October 1990 to December 1993. Overall, their extensive work experience encompasses roles in executive leadership, clinical development, medical affairs, marketing, and research.

Ivo Timmermans obtained their MD in Medicine from Radboud University, where they studied from 1981 to 1990. Ivo later pursued further education at Henley Business School, completing an MBA program from 2000 to 2003. The field of study for their MBA is not specified.